What do systematic reviews say?

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1 [0.78, 1.28]
  2 studies · 402 participants
  Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1.78 [1.4, 2.26]
  2 studies · 402 participants
  Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 2.38 [1.07, 5.3]
  2 studies · 402 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 2.01 [1.32, 3.07]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.79 [1.11, 2.9]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 4.68 [0.58, 37.68]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.18 [0.06, 0.54]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.28 [0.09, 0.92]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.07 [0, 1.23]
  1 study · 60 participants
  Low

Tacrolimus vs mycophenolate mofetil to maintain remission

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low